All In Biotech

Free tool

FAERS Monitor: Uroxatral

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021287 or its brand name (Uroxatral, Alfuzosin Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

3,374

Serious

1,950

58% of reports

Hospitalization

1,001

Death reported

242

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness252
  • drug ineffective206
  • fatigue200
  • dyspnoea145
  • asthenia132
  • nausea132
  • fall126
  • diarrhoea124
  • headache119
  • hypotension102
  • syncope97
  • insomnia94
  • malaise92
  • pain90
  • back pain86

Reports by year received

View as table
YearReports
2004279
2005270
2006180
2007129
2008140
2009183
2010301
2011312
2012275
2013103
201487
2015177
2016196
2017163
2018127
2019102
2020117
202195
202230
202323
202431
202532
202622

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,785 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
syncopeSignal976.05.0405
hypotensionSignal1023.22.6151
dizzinessSignal2523.22.8377
fallSignal1262.42.099
back painSignal862.31.963
insomniaSignal942.21.861
astheniaSignal1322.21.986
fatigue2001.61.446
dyspnoea1451.61.433
malaise921.31.16
diarrhoea1241.21.04
headache1191.21.03
nausea1321.00.90
drug ineffective2061.00.90
pain900.90.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.